Vasomera
Modify Date: 2024-09-17 18:35:01
Vasomera structure
|
Common Name | Vasomera | ||
|---|---|---|---|---|
| CAS Number | 1416067-68-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of VasomeraVasomera is a stable long-acting vasoactive intestinal peptide (VIP) agonist. Vasomera acts on the G-protein-coupled VPAC2-receptors. Vasomera can be used for the research of cardiomyopathy associated with dystrophinopathies[1]. |
| Name | Vasomera |
|---|
| Description | Vasomera is a stable long-acting vasoactive intestinal peptide (VIP) agonist. Vasomera acts on the G-protein-coupled VPAC2-receptors. Vasomera can be used for the research of cardiomyopathy associated with dystrophinopathies[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Vasomera (i.v.; 7.5 μg/kg/min; single) improves arterial elastance and ventriculo-arterial coupling and improves indices of diastolic function (i.e., lusitropy) in animals with chronic renoprival hypertension mimicking heart failure with preserved ejection fraction (HFpEF)[1]. Animal Model: Rats[1] Dosage: 7.5 μg/kg Administration: IV, 7.5 μg/kg/min, single Result: Decreased the estimated arterial elastance, improved ventriculo-arterial coupling, reduced filling pressures, accelerated the time-constant of relaxation and improved compliance. |
| References |
| No Any Chemical & Physical Properties |